BMRN News and Press, BioMarin Pharmaceutical Inc. From 02/08/24

BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced...

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress PR Newswire New Seven-Year Follow-Up Phase 2 Study Results Showed Durable Hemostati...

2024-01-30 14:30:03 ET Piper Sandler analyst issues UNDERPERFORM recommendation for BMRN on January 30, 2024 02:00PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $89.795 at issue of the analyst recommendation. The overall analyst consensu...

2024-01-21 09:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. U.S. equities rose in ...

2024-01-19 14:33:49 ET Summary BioMarin Pharmaceutical is a biotech company that focuses on delivering enzyme products for rare genetic disorders. The company has launched two new products, Voxzogo for Achondroplasia and Valoctocogene Roxaparvovec (Roctavian) for severe hemophilia...

2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA PR Newswire SAN RAFAEL, Calif. , Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announ...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-21 11:45:02 ET RBC Capital analyst issues SECTOR PERFORM recommendation for BMRN on December 21, 2023 12:00PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $94.52 at issue of the analyst recommendation. The overall analyst consen...